Eichler C, Kaden J, May G
Abteilung für experimentelle Organtransplantation, Bereiches Medizin (Charité), Humboldt-Universität zu Berlin.
Z Urol Nephrol. 1990 Aug;83(8):425-9.
In a retrospective study of 326 patients which have been received a renal allograft between 1985 and 1988 at the Berlin Kidney Transplant Centre, all recipients were divided into 3 groups according to their antibody status against cytomegalovirus (IgM+/IgG+; IgM-/IgG+; IgM-/IgG-). Frequency and severity of CMV infections in the early period after kidney transplantation have been compared. Primary infections could be observed in 51/112 (45.5%) patients (group 3), secondary infections in 60/190 (31.6%) patients (group 2). In 7.4% of all recipients (24/326) CMV-specific IgM antibodies could be found at the time of transplantation (group 1). In primary infections the patients have had a significantly higher frequency of moderate or severe CMV diseases as in secondary infections (24.4 vs. 8.3%). In group 3 this frequency was 16.7%. In conclusion, it is not necessary to select renal allograft recipients according their positive CMV-IgM-antibody status, but a close-meshed posttransplant control is indicated.
在一项对1985年至1988年间在柏林肾脏移植中心接受同种异体肾移植的326例患者的回顾性研究中，所有受者根据其针对巨细胞病毒的抗体状态分为3组（IgM+/IgG+；IgM-/IgG+；IgM-/IgG-）。比较了肾移植术后早期巨细胞病毒感染的频率和严重程度。在51/112例（45.5%）患者中观察到原发性感染（第3组），在60/190例（31.6%）患者中观察到继发性感染（第2组）。在所有受者的7.4%（24/326）中，移植时可检测到巨细胞病毒特异性IgM抗体（第1组）。原发性感染患者中中度或重度巨细胞病毒疾病的发生率显著高于继发性感染患者（24.4%对8.3%）。在第3组中，这一发生率为16.7%。总之，没有必要根据受者巨细胞病毒IgM抗体状态阳性来选择同种异体肾移植受者，但移植后需要进行密切监测。
